LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01828112
First received: April 2, 2013
Last updated: April 25, 2016
Last verified: April 2016
  Purpose
The primary purpose of the study is to compare the antitumor activity of LDK378 vs. chemotherapy in patients previously treated with chemotherapy (platinum doublet) and crizotinib.

Condition Intervention Phase
Non-Small Cell Lung Cancer
Drug: LDK378
Drug: pemetrexed
Drug: docetaxel
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase III, Multicenter, Randomized, Open-label Study of Oral LDK378 Versus Standard Chemotherapy in Adult Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer Who Have Been Treated Previously With Chemotherapy (Platinum Doublet) and Crizotinib

Resource links provided by NLM:


Further study details as provided by Novartis:

Primary Outcome Measures:
  • Progression Free Survival (PFS) [ Time Frame: Month 18 ] [ Designated as safety issue: No ]
    PFS which is defined as the time from the date of randomization to the date of the first radiologically documented disease progression or death due to any cause.


Secondary Outcome Measures:
  • Overall Survival (OS) [ Time Frame: Month 18 ] [ Designated as safety issue: No ]
    OS defined as time from date of randomization to date of death due to any cause

  • Overall Response Rate (ORR) [ Time Frame: Month 18 ] [ Designated as safety issue: No ]
    ORR is defined as the proportion of patients with a best overall response defined as complete response (CR) or partial response (PR); (CR+PR)

  • Duration of Response (DOR) [ Time Frame: Month 18 ] [ Designated as safety issue: No ]
    DOR is defined as the time from date of first documented CR or PR to date of first documented disease progression or death due to underlying cancer

  • Disease Control Rate (DCR) [ Time Frame: Month 18 ] [ Designated as safety issue: No ]
    DCR is defined as the proportion of patients with best overall response of CR, PR, or stable disease (SD)

  • Time to response (TTR) [ Time Frame: Month 18 ] [ Designated as safety issue: No ]
    TTR is defined as the time from date of randomization to date of first documented response (CR or PR)


Enrollment: 230
Study Start Date: June 2013
Estimated Study Completion Date: August 2018
Estimated Primary Completion Date: August 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: LDK378 Drug: LDK378
Oral LDK378 750 mg once daily
Active Comparator: pemetrexed or docetaxel Drug: pemetrexed
pemetrexed is 500 mg/m2 IV every 21 days
Drug: docetaxel
docetaxel is 75 mg/m2 every 21 days

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patient has a histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK) positive as assessed by the FDA approved Abbott FISH Test.
  2. Patient has stage IIIB or IV diagnosis and must have received one or two prior regimens (including platinum- doublet) of cytotoxic chemotherapy for the treatment of locally advanced or metastatic NSCLC.
  3. Patient has at least one measurable lesion as defined by RECIST 1.1. A previously irradiated site lesion may only be counted as a target lesion if there is clear sign of progression since the irradiation

Exclusion Criteria:

  1. Patient with known hypersensitivity to any of the excipients of LDK378 (microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide and magnesium stearate)
  2. Patient with a history of severe hypersensitivity reaction to pemetrexed or docetaxel or any known excipients of these drugs.
  3. Patient with symptomatic central nervous system (CNS) metastases who is neurologically unstable or has required increasing doses of steroids within the 2 weeks prior to screening to manage CNS symptoms.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01828112

  Hide Study Locations
Locations
United States, Arizona
Arizona Oncology Associates PC- NAHOA
Sedona, Arizona, United States, 86336
United States, Arkansas
Highlands Oncology Group SC-1
Fayetteville, Arkansas, United States, 72703
United States, California
University of California San Francisco Dept. of UCSF
San Francisco, California, United States, 94101
United States, Florida
Memorial Cancer Institute SC
Hollywod, Florida, United States, 33021
Cancer Specialists of North Florida
Jacksonville, Florida, United States, 32256
University of Miami SC
Miami, Florida, United States, 33136
United States, Illinois
Loyola University Medical Center /Cardinal Bernardin Cancer SC
Maywood, Illinois, United States, 60153
United States, Iowa
University of Iowa Hospitals & Clinics Oncology
Iowa City, Iowa, United States, 52242
United States, Massachusetts
Massachusetts General Hospital SC-8
Boston, Massachusetts, United States, 02114
United States, Oklahoma
Oklahoma Cancer Specialists and Research Institute SC-2
Tulsa, Oklahoma, United States, 74136
United States, Tennessee
Sarah Cannon Research Institute SC-5
Nashville, Tennessee, United States, 37203
United States, Texas
Texas Oncology-Sugarland
Sugarland, Texas, United States, 77479
Texas Oncology Cancer Care & Research Center
Waco, Texas, United States, 76712
United States, Virginia
Virginia Cancer Specialists, PC SC Virginia Cancer Specialists
Fairfax, Virginia, United States, 22031
United States, Washington
Swedish Cancer Institute SC-1
Seattle, Washington, United States, 98104
Wenatchee Valley Medical Center SC
Wenatchee, Washington, United States, 98801
Belgium
Novartis Investigative Site
Bruxelles, Belgium, 1200
Novartis Investigative Site
Bruxelles, Belgium, 1000
Novartis Investigative Site
Edegem, Belgium, 2650
Novartis Investigative Site
Leuven, Belgium, 3000
Canada, Ontario
Novartis Investigative Site
Toronto, Ontario, Canada, M5G 2M9
France
Novartis Investigative Site
Besancon cedex, France, 25030
Novartis Investigative Site
Brest, France, 29200
Novartis Investigative Site
Caen Cedex, France, 14021
Novartis Investigative Site
Le Mans Cedex 09, France, 72037
Novartis Investigative Site
Lille Cedex, France, 59020
Novartis Investigative Site
Marseille cedex 20, France, 13915
Novartis Investigative Site
Mulhouse cedex, France, 68070
Novartis Investigative Site
Paris, France, 75970
Novartis Investigative Site
Paris, France, 75015
Novartis Investigative Site
Strasbourg, France, F-67085
Novartis Investigative Site
Suresnes, France, 92150
Germany
Novartis Investigative Site
Bad Berka, Germany, 99437
Novartis Investigative Site
Berlin, Germany, 13125
Novartis Investigative Site
Essen, Germany, 45147
Novartis Investigative Site
Esslingen, Germany, 73730
Novartis Investigative Site
Frankfurt, Germany, 60590
Novartis Investigative Site
Grosshansdorf, Germany, 22947
Novartis Investigative Site
Heidelberg, Germany, 69120
Novartis Investigative Site
Koeln, Germany, 51109
Novartis Investigative Site
Tuebingen, Germany, 72076
Novartis Investigative Site
Ulm, Germany, 89081
Hong Kong
Novartis Investigative Site
Hong Kong, Hong Kong
Ireland
Novartis Investigative Site
Limerick, Co Limerick, Ireland
Novartis Investigative Site
Dublin 4, Ireland
Israel
Novartis Investigative Site
Kfar-Sava, Israel, 4428164
Novartis Investigative Site
Ramat Gan, Israel, 5266202
Italy
Novartis Investigative Site
Avellino, AV, Italy, 83100
Novartis Investigative Site
Monza, MB, Italy, 20900
Novartis Investigative Site
Milano, MI, Italy, 20132
Novartis Investigative Site
Perugia, PG, Italy, 06129
Novartis Investigative Site
Pisa, PI, Italy, 56124
Novartis Investigative Site
Aviano, PN, Italy, 33081
Novartis Investigative Site
Reggio Emilia, RE, Italy, 42123
Novartis Investigative Site
Roma, RM, Italy, 00189
Novartis Investigative Site
Orbassano, TO, Italy, 10043
Novartis Investigative Site
Verona, VR, Italy, 37126
Japan
Novartis Investigative Site
Nagoya, Aichi, Japan, 464-8681
Novartis Investigative Site
Kashiwa, Chiba, Japan, 277-8577
Novartis Investigative Site
Fukuoka-city, Fukuoka, Japan, 812-8582
Novartis Investigative Site
Akashi, Hyogo, Japan, 673-8558
Novartis Investigative Site
Niigata-city, Niigata, Japan, 951-8520
Novartis Investigative Site
Okayama-city, Okayama, Japan, 700-8558
Novartis Investigative Site
Hirakata-city, Osaka, Japan, 573-1191
Novartis Investigative Site
OsakaSayama, Osaka, Japan, 589-8511
Novartis Investigative Site
Takatsuki-city, Osaka, Japan, 569-8686
Novartis Investigative Site
Koto, Tokyo, Japan, 135-8550
Novartis Investigative Site
Fukuoka, Japan, 811-1395
Novartis Investigative Site
Osaka, Japan, 537-8511
Korea, Republic of
Novartis Investigative Site
Seoul, Korea, Korea, Republic of, 137-701
Novartis Investigative Site
Seoul, Korea, Korea, Republic of, 03722
Novartis Investigative Site
Seoul, Korea, Korea, Republic of, 05505
Novartis Investigative Site
Seoul, Korea, Korea, Republic of, 06351
Novartis Investigative Site
Seoul, Korea, Korea, Republic of, 03080
Lebanon
Novartis Investigative Site
Beirut, Lebanon, 166830
Netherlands
Novartis Investigative Site
Amsterdam, Netherlands, 1081 HV
Novartis Investigative Site
Groningen, Netherlands, 9713 GZ
Portugal
Novartis Investigative Site
Coimbra, Portugal, 3041-853
Novartis Investigative Site
Lisboa, Portugal, 1649-035
Russian Federation
Novartis Investigative Site
Moscow, Russian Federation, 115478
Novartis Investigative Site
Moscow, Russian Federation, 143423
Novartis Investigative Site
Saint Petersburg, Russian Federation, 197022
Singapore
Novartis Investigative Site
Singapore, Singapore, 119228
Novartis Investigative Site
Singapore, Singapore, 169610
Spain
Novartis Investigative Site
Sevilla, Andalucia, Spain, 41013
Novartis Investigative Site
Sevilla, Andalucia, Spain, 41017
Novartis Investigative Site
Sabadell, Barcelona, Spain, 08208
Novartis Investigative Site
Barcelona, Catalunya, Spain, 08035
Novartis Investigative Site
Hospitalet de LLobregat, Catalunya, Spain, 08907
Novartis Investigative Site
Barcelona, Cataluña, Spain, 08028
Novartis Investigative Site
Valencia, Comunidad Valenciana, Spain, 46010
Novartis Investigative Site
La Coruna, Galicia, Spain, 15006
Novartis Investigative Site
Santiago de Compostela, Galicia, Spain, 15706
Novartis Investigative Site
Majadahonda, Madrid, Spain, 28222
Novartis Investigative Site
Madrid, Spain, 28034
Novartis Investigative Site
Madrid, Spain, 28046
Novartis Investigative Site
Madrid, Spain, 28041
Switzerland
Novartis Investigative Site
Luzern, Switzerland, 6000
Novartis Investigative Site
St. Gallen, Switzerland, 9007
Turkey
Novartis Investigative Site
Ankara, Turkey, 06100
Novartis Investigative Site
Fatih / Istanbul, Turkey, 34098
Novartis Investigative Site
Pendik / Istanbul, Turkey, 1330
United Kingdom
Novartis Investigative Site
Cheltenham, Gloucestershire, United Kingdom, GL53 7AN
Novartis Investigative Site
Hants, Southampton, United Kingdom, SO9 5NY
Novartis Investigative Site
Aberdeen, United Kingdom, AB25 2ZN
Novartis Investigative Site
Leicester, United Kingdom, LE1 5WW
Novartis Investigative Site
London, United Kingdom, SE1 9RT
Novartis Investigative Site
Manchester, United Kingdom, M20 2BX
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01828112     History of Changes
Other Study ID Numbers: CLDK378A2303  2012-005637-36 
Study First Received: April 2, 2013
Last Updated: April 25, 2016
Health Authority: United States: Food and Drug Administration
Belgium: Federal Agency for Medicinal Products and Health Products
Canada: Canadian Health Authorities
France: Haute Autorité de Santé Transparency Commission
Germany: Federal Institute for Drugs and Medical Devices
Hong Kong: Department of Health (DoH), pharmaceutical services
Ireland:
Isreal: Ministry of Health
Italy: Ministry of Health
Japan: Ministry of Health, Labor and Welfare
Netherlands: Medicines Evaluation Board (MEB)
Russia:Ministry of Public Health of Russian Federation
Singapore: Health Sciences Authority
South Korea: Korea Food and Drug Administration (KFDA)
Spain: Spanish Agency of Medicines
Sweden: Medical Products Agency
Switzerland: Swissmedic
Turkey: Ministry of Health
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Portugal: Ethics Committee for Clinical Research
Luxembourg: Ministère de la Santé

Keywords provided by Novartis:
Non-Small Cell Lung Cancer, ALK, LDK378

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Docetaxel
Ceritinib
Pemetrexed
Crizotinib
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Folic Acid Antagonists
Nucleic Acid Synthesis Inhibitors
Protein Kinase Inhibitors

ClinicalTrials.gov processed this record on July 21, 2016